Chengcai Li

Dr. Chengcai Li


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 April 2021 in Cellular and Molecular Neurobiology
Verified
Journal Article
Closed access
PDF file
CLChengcai Li
Chengcai Li
ZXZhiping Xie
Zhiping Xie
ZXZelong Xing
Zelong Xing
HZHuaxin Zhu
Huaxin Zhu
WZWu Zhou
Wu Zhou
MLMeihua Li
Meihua Li

6 September 2024 in Discover Oncology
Verified
Journal Article
Open access
PDF file
WLWei Liu
Wei Liu
BJBo Jia
Bo Jia
ZWZan Wang
Zan Wang
CLChengcai Li
Chengcai Li
NLNanding Li
Nanding Li
JWJiwei Wang
Jiwei Wang
Glioma is the most aggressive intracranial malignancy and is associated with poor survival rates and limited quality of life, impairing neuropsychological function and cognitive competence in survivors. The Proteasome Subunit Alpha Type-5 (PSMA5) is a multicatalytic proteinase complex that has been linked with tumor progression but is rarely reported in glioma. This study investigates the expression pattern, prognostic characteristics, and potential biological functions of PSMA5 in glioma. PSMA5 was significantly overexpressed in 28 types of cancer when compared to normal tissue. Furthermore, elevated levels of PSMA5 were observed in patients with wild-type isocitrate dehydrogenase 1 and exhibited a positive correlation with tumor grade. It was also found to be a standalone predictor of outcomes in glioma patients. Additionally, inhibiting PSMA5-induced cell cycle arrest may provide a therapeutic option for glioma.

25 October 2025 in World Neurosurgery
Verified
Journal Article
Open access
ZYZhijie Yan
Zhijie Yan
CWChunliang Wang
Chunliang Wang
RLRongbo Liao
Rongbo Liao
HYHeqiang Yang
Heqiang Yang
ZDZihan Ding
Zihan Ding
CLChengcai Li
Chengcai Li
To investigate the association of magnetic resonance imaging (MRI) and peripheral blood inflammatory biomarkers with follow-up American Spinal Injury Association Impairment Scale (AIS) grade in patients with acute traumatic spinal cord injury in the cervical region (TSCI-C) and assess whether combining MRI biomarkers with peripheral white blood cell (WBC) count improves AIS grade prediction. This retrospective cohort study included 307 patients with acute TSCI-C. The patients underwent peripheral blood tests within 12 hours and preoperative MRI within 48 hours of injury. MRI biomarkers included maximum cervical canal compromise, maximum spinal cord compression, intramedullary lesion length, Brain and Spinal Cord Injury Center score, and sagittal grade. Peripheral blood inflammatory biomarkers included WBCs, neutrophils, and neutrophil ratio. Data-driven nonlinear principal component analysis, correlation analysis, and optimal scaling multivariate regression were conducted to predict neurologic impairment at follow-up. Maximum canal compromise and maximum spinal cord compression loaded positively on second principal component, while the Brain and Spinal Cord Injury Center score, sagittal grade, and intramedullary lesion length loaded negatively. The WBC count was modeled quadratically (WBC2), showing an initial increase from grade A to C, followed by a decrease, resembling a quadratic function. Despite negative loadings on first and second principal components, the WBC count had low classification ability for AIS grade. Receiver operating characteristic analysis showed that combining MRI biomarkers with WBC count yielded a higher area under the curve than the MRI-only model. We recommend using a combined approach of MRI biomarkers and peripheral WBC count to improve the prediction of neurological impairment in TSCI-C patients, enhancing the sensitivity and specificity of AIS grade prediction.